Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Hmn-214. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 1/20 | 0.83 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | SNCA | P37840 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.35 |
| ▸ | CAMK2G | Q13555 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.34 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hmn-214 SCHEMBL5173985 | 0.99 | MET (0.84) | METSTAT3SNCAALDH1A1MAPT | |
| Hmn-214 SCHEMBL5174071 | 0.92 | MET (0.80) | METSTAT3SNCAALDH1A1MAPT | |
| Hmn-214 SCHEMBL5173713 | 0.91 | MET (1.00) | METSTAT3SNCAALDH1A1MAPT | |
| Hmn-214 SCHEMBL29360540 | 0.91 | MET (1.00) | METSTAT3SNCAALDH1A1MAPT | |
| Hmn-214 SCHEMBL5173720 | 0.91 | MET (1.00) | METSTAT3SNCAALDH1A1MAPT | |
| Hmn-214 SCHEMBL6546098 | 0.91 | MET (0.81) | METSTAT3SNCAALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL5174656 | 0.81 | MET (0.69) | METSTAT3ALDH1A1LMNAKEAP1 | |
| Hydrochloric Acid SCHEMBL5174666 | 0.81 | MET (0.69) | METSTAT3ALDH1A1LMNAKEAP1 | |
| Hydrochloric Acid SCHEMBL5175657 | 0.81 | MET (0.77) | METSTAT3SNCAALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL5175648 | 0.81 | MET (0.77) | METSTAT3SNCAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1238974-B1 | HETEROCYCLE DERIVATIVES AND DRUGS | NIPPON SHINYAKU CO LTD (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-6787546-B2 | POTENT ANTICANCER ACTIVITY; WATER SOLUBLE; INJECTION 4-(2-(2-(N-(4-METHOXYBENZENESULFONYL)-N -PIPERIDINOACETYLAMINO)PHENYL)ETHENYL)PYRIDINE 1-OXIDE HYDROCHLORIDE | NIPPON SHINYAKU CO., LTD. (JP) | 2004-09-07 | — | — | US | disclosed |
| US-20030022884-A1 | Heterocycle derivatives and drugs | NIPPON SHINYAKU CO., LTD. (JP) | 2003-01-30 | — | — | US | disclosed |
| EP-1238974-A1 | HETEROCYCLE DERIVATIVES AND DRUGS | Nippon Shinyaku Co., Ltd. (JP) | 2002-09-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022884-A1 | Heterocycle derivatives and drugs | ABCC5, CYP3A5, CYP2D6 | MET 988/4885STAT3 3973/4885SNCA 2744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.